本帖最后由 老马 于 2012-1-13 21:20 编辑 , P7 R* M C' e$ J
5 d" l# s9 D( Y# M. [
爱必妥和阿瓦斯丁的比较 p- |" K. }, b1 {* B7 l
& y3 B0 j- |* U9 B; c8 whttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/+ Y8 U7 {- Z7 z! ^
- k- y- e& ~" h) _( I
+ l7 j9 f4 o" Y$ R7 Q3 {http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/6 z1 o; K) h& w$ M( j! e, r
==================================================' E0 [& U. ~. C! t7 ~
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)( z5 R. r( _( {, b: _
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point., E. k/ ?) P4 F" ]: `1 g$ E) i7 b* W
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported." |. ]4 g# S; W& \" k, i- |
|
显身卡
